Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging
- PMID: 20009056
- PMCID: PMC2838501
- DOI: 10.1001/jama.2009.1836
Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging
Abstract
Context: The adipokine leptin facilitates long-term potentiation and synaptic plasticity in the hippocampus, promotes beta-amyloid clearance, and improves memory function in animal models of aging and Alzheimer disease (AD).
Objective: To relate baseline circulating leptin concentrations in a community-based sample of individuals without dementia to incident dementia and AD during follow-up and magnetic resonance imaging (MRI) measures of brain aging in survivors.
Design, setting, and participants: Prospective study of plasma leptin concentrations measured in 785 persons without dementia (mean [SD] age, 79 [5] years; 62% female), who were in the Framingham original cohort at the 22nd examination cycle (1990-1994). A subsample of 198 dementia-free survivors underwent volumetric brain MRI between 1999 and 2005, approximately 7.7 years after leptin was assayed. Two measures of brain aging, total cerebral brain volume and temporal horn volume (which is inversely related to hippocampal volume) were assessed.
Main outcome measure: Incidence of dementia and AD during follow-up until December 31, 2007.
Results: During a median follow-up of 8.3 years (range, 0-15.5 years), 111 participants developed incident dementia; 89 had AD. Higher leptin levels were associated with a lower risk of incident dementia and AD in multivariable models (hazard ratio per 1-SD increment in log leptin was 0.68 [95% confidence interval, 0.54-0.87] for all-cause dementia and 0.60 [95% confidence interval, 0.46-0.79] for AD). This corresponds to an absolute AD risk over a 12-year follow-up of 25% for persons in the lowest quartile (first quartile) vs 6% for persons in the fourth quartile of sex-specific leptin levels. In addition, a 1-SD elevation in plasma leptin level was associated with higher total cerebral brain volume and lower temporal horn volume, although the association of leptin level with temporal horn volume did not reach statistical significance.
Conclusion: Circulating leptin was associated with a reduced incidence of dementia and AD and with cerebral brain volume in asymptomatic older adults.
Conflict of interest statement
Figures
Comment in
-
Late-life dementias: does this unyielding global challenge require a broader view?JAMA. 2009 Dec 16;302(23):2593-4. doi: 10.1001/jama.2009.1863. JAMA. 2009. PMID: 20009062 Free PMC article. No abstract available.
-
Leptin levels and Alzheimer disease.JAMA. 2010 Apr 21;303(15):1478; author reply 1478-9. doi: 10.1001/jama.2010.436. JAMA. 2010. PMID: 20407052 No abstract available.
Similar articles
-
Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes.JAMA Neurol. 2019 May 1;76(5):598-606. doi: 10.1001/jamaneurol.2018.4666. JAMA Neurol. 2019. PMID: 30830207 Free PMC article.
-
Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study.JAMA Neurol. 2014 Jan;71(1):55-61. doi: 10.1001/jamaneurol.2013.4781. JAMA Neurol. 2014. PMID: 24276217 Free PMC article.
-
Circulating ceramide ratios and risk of vascular brain aging and dementia.Ann Clin Transl Neurol. 2020 Feb;7(2):160-168. doi: 10.1002/acn3.50973. Epub 2020 Jan 16. Ann Clin Transl Neurol. 2020. PMID: 31950603 Free PMC article.
-
Autonomic nervous system flexibility for understanding brain aging.Ageing Res Rev. 2023 Sep;90:102016. doi: 10.1016/j.arr.2023.102016. Epub 2023 Jul 17. Ageing Res Rev. 2023. PMID: 37459967 Free PMC article. Review.
-
Prenatal exposure to undernutrition is associated with a specific lipid profile predicting future brain aging.NPJ Aging. 2024 Sep 30;10(1):42. doi: 10.1038/s41514-024-00169-x. NPJ Aging. 2024. PMID: 39349457 Free PMC article. Review.
Cited by
-
Leptin bioavailability and markers of brain atrophy and vascular injury in the middle age.Alzheimers Dement. 2024 Sep;20(9):5849-5860. doi: 10.1002/alz.13879. Epub 2024 Aug 12. Alzheimers Dement. 2024. PMID: 39132759 Free PMC article.
-
The potential positive effect of periodontal treatment on brain function activity using functional magnetic resonance imaging analysis.J Dent Sci. 2024 Jul;19(3):1811-1818. doi: 10.1016/j.jds.2023.09.024. Epub 2023 Oct 4. J Dent Sci. 2024. PMID: 39035336 Free PMC article.
-
Novel Leptin-Based Therapeutic Strategies to Limit Synaptic Dysfunction in Alzheimer's Disease.Int J Mol Sci. 2024 Jul 4;25(13):7352. doi: 10.3390/ijms25137352. Int J Mol Sci. 2024. PMID: 39000459 Free PMC article. Review.
-
Neuro-Adipokine Crosstalk in Alzheimer's Disease.Int J Mol Sci. 2024 May 29;25(11):5932. doi: 10.3390/ijms25115932. Int J Mol Sci. 2024. PMID: 38892118 Free PMC article. Review.
-
Plasma Leptin and Alzheimer Protein Pathologies Among Older Adults.JAMA Netw Open. 2024 May 1;7(5):e249539. doi: 10.1001/jamanetworkopen.2024.9539. JAMA Netw Open. 2024. PMID: 38700863 Free PMC article.
References
-
- Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002;51(4):1256–1262. - PubMed
-
- 2008 Alzheimer’s disease facts and figures. Alzheimers Dement. 2008;4(2):110–133. - PubMed
-
- Wolf PA, Beiser A, Elias MF, Au R, Vasan RS, Seshadri S. Relation of obesity to cognitive function: importance of central obesity and synergistic influence of concomitant hypertension. The Framingham Heart Study. Curr Alzheimer Res. 2007;4(2):111–116. - PubMed
-
- Elmquist JK, Maratos-Flier E, Saper CB, Flier JS. Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci. 1998;1(6):445–450. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 NS017950/NS/NINDS NIH HHS/United States
- R01 AG016495/AG/NIA NIH HHS/United States
- R01 AG016495-10/AG/NIA NIH HHS/United States
- R01 AG031287-01A2/AG/NIA NIH HHS/United States
- AG08122/AG/NIA NIH HHS/United States
- R01 AG008122/AG/NIA NIH HHS/United States
- R01 AG033193/AG/NIA NIH HHS/United States
- AG031287/AG/NIA NIH HHS/United States
- K24 HL004334-08/HL/NHLBI NIH HHS/United States
- N01HC25195/HL/NHLBI NIH HHS/United States
- R01 DK080739/DK/NIDDK NIH HHS/United States
- N01 HV028178/HV/NHLBI NIH HHS/United States
- N01-HC-25195/HC/NHLBI NIH HHS/United States
- R01 AG008122-10/AG/NIA NIH HHS/United States
- R01 NS17950/NS/NINDS NIH HHS/United States
- N01 HC025195/HC/NHLBI NIH HHS/United States
- AG033193/AG/NIA NIH HHS/United States
- R01 NS017950-28/NS/NINDS NIH HHS/United States
- 2K24HL04334/HL/NHLBI NIH HHS/United States
- R01 DK080739-02/DK/NIDDK NIH HHS/United States
- N01HV28178/HV/NHLBI NIH HHS/United States
- K24 HL004334/HL/NHLBI NIH HHS/United States
- P30 AG010129-18/AG/NIA NIH HHS/United States
- R01 AG033193-01/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- R01 AG16495/AG/NIA NIH HHS/United States
- R01 AG031287/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
